Latest Headlines

Latest Headlines

Japan's Eisai to present papers on Lenvima clinical data at European Cancer Congress

Japan's Eisai said it will present a series of clinical results on Lenvima (lenvatinib) and Halaven (eribulin), among other papers, at the European Cancer Congress, as the company works to grow its key oncology business.

China plans public health push on cancer, wants to expand screening

China plans a public health campaign on cancer that over the next three years will see screening for early detection expanded by nearly one-third, spur new drug development and direct focus on prevention that covers smoking, China Daily reported.

Oncology trials in China may see pilot program for 60-day IND decision

Investigational new drug applications for oncology in China may see a 60-day deadline for a thumbs up, or down, placing the country on a path already followed by Singapore, Taiwan and South Korea for quick early-stage decisions.

BeiGene plans wider footprint in China with Suzhou development site

BeiGene is moving to Suzhou, in part, with plans to branch out from its capital city headquarters and develop a novel oncology drug operation that includes a cGMP manufacturing facility in Suzhou's BioBAY, the company said in a press release.

Singapore's Asian American Medical eyes oncology expansion in southern China

Singapore-listed Asian American Medical Group said it paid S$19.6 million ($13.9 million) to buy 60% of Rich Tree Land to develop an oncology diagnostics and treatment center in Zhuhai, southern China. 

Abrupt departure of Novogen CEO followed upbeat Anisina presentation

The abrupt departure of Australia's Novogen Chairman Graham Kelly this week came after the jointly listed Nasdaq and Australian Stock Exchange biotech presented details of an in vivo proof of concept study for anti-tropomyosin drug candidate Anisina in July in the U.S.

HK-based Chi-Med cements Hutchison MediPharma control with eyes on oncology candidates

Hong Kong-based Hutchison China MediTech has cemented its already majority stake in Hutchison MediPharma via a share exchange deal with Japan's Mitsui & Co. in a disclosure notice with few details, but ahead of study results later this year on a promising candidate for China approval.

China's BeiGene completes $97M financing for targeted oncology candidates

China's BeiGene said it has completed financing of more than CNY450 million ($75 million) from initial angel and strategic investors as well as new investors Hillhouse Capital and CITIC PE, joined by an unnamed "blue chip U.S. public investment fund" specializing in life sciences.

SV Bio changes name to Lifecode, plans rollout of NGS cancer assay

Alongside the launch of a next generation sequencing-based oncology assay, Silicon Valley Biosystems is also rolling out a new name to reflect its mission of providing practical genetic information to patients.

Janssen rethinks drug discovery in a changing R&D environment

For William Strohl, the new head of Janssen's Biotechnology Center of Excellence, the future of drug R&D involves novel targets, "fit-for-purpose" antibodies and lots of collaborations.